



Jeremy Grata  
[grata@artemisbiomedical.com](mailto:grata@artemisbiomedical.com)

**Technology That's Rewriting The  
Diabetic's Story**

# **OVERVIEW**

**The Diabetes Epidemic**

**The Diabetic's Dilemma**

**Who Is Artemis?**

**Investor Offer**

**The Value of the Technology**

**Financials**

**Timing and Milestones**

# There is a Diabetes Epidemic

- 3<sup>rd</sup> Leading cause of death
- 1 in 16 People in the world have been diagnosed
- 1 in 10 People in the US have been diagnosed
- 1 in 3 People in the US currently have diabetes or are pre-diabetic
  - 1 in 2 By 2025
- Nearly \$2 Trillion are spent every year addressing diabetes
  - 1 out of every 4 Healthcare dollars address diabetes

# The Diabetic's Dilemma

- 22% of people with diabetes must test blood glucose 4 or more times per day to avoid severe medical issues
- The only test method reliable and accurate enough for all diabetic use cases is the finger prick glucometer
- Finger prick glucometers are painful, inconvenient and require expensive supplies for each use





# The Diabetic's Dilemma

- Other available glucometers
  - Frequently cause pain and irritation
  - Measure glucose in skin, not glucose in blood
  - Are not approved for use in all cases
  - **Do Not Replace the Finger Prick Glucometer**
- What is needed is a pain-free, easy to use, blood glucometer
  - An Artemis Device; the **ONLY** finger prick glucometer replacement



# Who Is Artemis?

- Artemis is bringing finger prick accuracy and reliability to diabetics in a hand held non-invasive pain free glucometer for all use cases
- We are a medical device company with unique patented technology resulting from years of successful non-invasive glucometer development efforts
- We are a small group of highly skilled individuals uniquely qualified to bring this non-invasive glucometer technology to market

# Artemis Investor Offer

- Seeking \$40M investment
- Funds 5 year glucometer commercialization effort
  - Funding for years 1 – 3 supports
    - Cash short fall
    - Device miniaturization, development and manufacturing readiness
  - Funding for Years 3 – 5 supports
    - Regulatory approval (CE and FDA)
    - Commercialization
- Sale or license of technology to major market share holder after commercialization in year 3

# The Real Value Of Artemis Technology

- Pain free testing
- Easy and convenient to use
- No additional cost or anxiety for frequent use
- Eliminates medical waste such as lancets, alcohol wipes and test strips
- Priced below the cost of a finger prick glucometer
- Validated performance to replace finger prick glucometers for all use cases





# Finance Summary

In 1000s

	Year 1	Year 2	Year 3	Year 4	Year 5	Total
Hardware Revenue	-	-	4,518.00	300,000.00	360,000.00	664,518.00
Subscription Revenue	-	-	468.52	98,272.24	339,672.24	438,413.00
<b>Total Revenue</b>	-	-	<b>4,986.52</b>	<b>398,272.24</b>	<b>699,672.24</b>	<b>1,102,931.00</b>
COGS	-	-	3,313.20	220,000.00	264,000.00	487,313.20
Gross Margin	-	-	<b>1,673.32</b>	<b>178,272.24</b>	<b>435,672.24</b>	<b>615,617.80</b>
Gross Margin %			34%	45%	62%	56%
Headcount & Related Expense	3,001.54	3,601.85	3,601.85	3,601.85	3,601.85	17,408.94
R&D Expense	5,639.38	7,037.63	970.00	910.00	680.00	15,237.00
Operating Expense	35.53	36.98	319.52	18,787.14	22,537.14	41,716.30
<b>Total Expense</b>	<b>8,676.45</b>	<b>10,676.45</b>	<b>4,891.37</b>	<b>23,298.99</b>	<b>26,818.99</b>	<b>74,362.24</b>
F&F	115.90	4.80	0.80	-	-	121.50
Manufacturing Equipment	-	841.50	341.00	930.00	-	2,112.50
IT Equipment	148.00	-	-	-	-	148.00
Capital Software	170.00	-	-	-	-	170.00
R&D Equipment	1,085.00	-	-	-	-	1,085.00
<b>Total CAPEX</b>	<b>1,518.90</b>	<b>846.30</b>	<b>341.80</b>	<b>930.00</b>	<b>-</b>	<b>3,637.00</b>
<b>Total Spend</b>	<b>10,195.35</b>	<b>11,522.75</b>	<b>8,546.37</b>	<b>244,228.99</b>	<b>290,818.99</b>	<b>565,312.44</b>
<b>Net Cash Flow</b>	<b>(10,195.35)</b>	<b>(11,522.75)</b>	<b>(3,559.85)</b>	<b>154,043.25</b>	<b>408,853.25</b>	<b>537,618.56</b>

# Milestones

Milestone	Description	Month	Cost
Technology Demonstrator	Laboratory sized device, COTS parts, with full measurement function	10	\$8.6M
Engineering Prototype	Handheld sized device, custom and COTS parts with full measurement function	22	\$21M
Manufacturing Prototype	Handheld device with full measurement function and production ready design	31	\$25M
Production/Trial Start	Final device design, Approval studies	32	\$26M
CE/MDA	Approval for EU sales	36	\$29M
FDA	Approval for US sales	60	\$40M



# Summary

- Artemis is bringing the first non-invasive, pain free, blood glucose monitor to the diabetic market
- \$40M Investment
- 5 Year effort
  - Sales beginning in the EU in year 3
  - Sale or license of technology after commercialization
  - FDA approval by year 5

# Q & A





# **WEBSITE**

**[www.artemisbiomedical.com](http://www.artemisbiomedical.com)**